The most frequently studied candidate gene for Neuroticism, depression, anxiety-related traits and disorders is the serotonin transporter (5-HTT)(
Lesch et al., 1996;
Alaerts et al., 2008;
Frodl et al., 2008;
Tadic et al., 2008;
Zaboli et al., 2008;
Xu et al., 2008). The gene SLC6A4 encodes the 5-HTT, a membrane protein that transports serotonin from synaptic spaces into presynaptic neurons. 5-HTT is the main target of the most widely used class of psychiatric drugs, the selective serotonin reuptake inhibitors (SSRIs). The SLC6A4 gene is on chromosome 17q11.1-q12. A functional insertion/deletion polymorphism is present in the regulatory region of the gene, and is referred as the 5-hydroxytryptamine-linked polymorphic region (5-HTTLPR). The short (S) allele (44-bp deletion) was found to be transcribed less efficiently than the long (L) allele, which results in a decreased 5-HTT expression and serotonin uptake in lymphoblasts (
Lesch et al., 1996). In a sample of 505 individuals,
Lesch et al. (1996) found that the NEO-PI-R Neuroticism was significantly associated with the 5-HTTLPR: individuals with the SS or SL genotypes had higher scores on Neuroticism than individuals with the LL genotype. Lesch et al. estimated that the polymorphism accounted for 3% to 4% of total variation and 7% to 9% of inherited variance of anxiety-related personality traits. Although the mechanism of action of the SSRIs are complex and do not simply fit hypotheses such as the “serotonin depletion” for depression (
Lacasse and Leo 2005), the association between the less active S allele and Neuroticism remains counterintuitive (
Lesch et al., 1996;
Arbelle et al., 2003; but see
Ansorge et al., 2004). Given that the SSRI therapeutic action is through blocking reuptake of serotonin, one would expect the less efficient S allele (which presumably reuptakes less serotonin) to be associated with lower Neuroticism.
Furthermore, the original report was replicated in a number of later studies (
Sen et al., 2004b;
Ricketts et al., 1998;
Greenberg et al., 2000;
Murakami et al., 1999), but others failed to find an association using general population (
Herbst et al., 2000;
Jorm et al., 1998;
Ball et al., 1997;
Ebstein et al., 1997;
Willis-Owen et al., 2005;
Munafo et al., 2008b;
Middeldorp et al., 2007) or clinical samples (
Mazzanti et al., 1998;
Gelernter et al., 1998), and some found an association in the opposite direction (
Brummett et al., 2003;
Van Gestel et al., 2002;
Arbelle et al., 2003;
Jorm et al., 2000). Inconsistent findings have been attributed to the use of admixed populations, but the true impact of population stratification in the field of molecular psychiatry is questionable (
Hutchison et al., 2004;
Gardner et al., 2008). Several meta-analyses have summarized the results (
Sen et al., 2004a;
Schinka et al., 2004;
Munafo et al., 2008b), and found no association when considering the entire set of studies. However, the choice of personality scale used was a significant moderating variable: In studies that used the Neuroticism scale of the NEO-PI-R, a small (
d ~ 0.2) but statistically significant effect was found. No effect was found when personality was assessed using the Harm Avoidance scale of the TCI or the Neuroticism scale of the EPQ. Another meta-analyses (
Munafo et al., 2005a) reported a moderating effect in the opposite direction, but this might be due to coding errors (
Munafo et al., 2005b).
The results of meta-analyses should be considered with caution because of the uncontrolled differences among studies, publication biases, unknown moderating variables, and other confounding factors. As argued by Munafo
et al., “Meta-analyses are therefore by no means perfect [...]. Very large, well-designed primary studies remain the most reliable way of obtaining reproducible results” (2005b). To date, the only large studies (~4,000 subjects) well-powered to detect small genetic effect did not support the hypothesis that the 5-HTTLPR is associated with Neuroticism, as measured with the EPQ (
Willis-Owen et al., 2005), or Harm Avoidance (
Munafo et al., 2008b). However, it is possible that when the phenotype is assessed with the NEO-PI-R an association between the 5-HTTLPR and Neuroticism could be found. To address this hypothesis, we examined in a large sample (~4,000 subjects) whether personality traits assessed with the NEO-PI-R are associated with the 5-HTTLPR and other variants in the serotonin transporter gene. This sample is part of the SardiNIA project (
Pilia et al., 2006), a multidisciplinary study that assessed multiple traits and performed a genome-wide association scan in a homogeneous sample from a founder population. Furthermore, we tested the association of the 5-HTTLPR and other variants in a sample from the Baltimore Longitudinal Study of Aging (BLSA). In the BLSA, most subjects have been assessed with the NEO-PI-R at multiple visits. Longitudinal studies have shown that the use of multiple measures yields larger estimates of heritability compared to studies based on single report (
Riemann et al., 1997;
Kendler et al., 1993). Aggregating data across multiple occasions should produce more robust results, less dependent on state-specific effects. Although the BLSA sample with 5-HTTLPR genotype is relatively small, the sample size of 548 individuals has a power higher than .80, at significance level
p = .01 two-tailed, to detect the differences on Neuroticism reported in recent meta-analyses (
d ~ .2)(
Sen et al., 2004a;
Schinka et al., 2004;
Munafo et al., 2008b). In addition to the 5-HTTLPR, in both samples we examine a number of single nucleotide polymorphisms (SNPs) that map in the SLC6A4 gene region for association with the Neuroticism related traits. These SNPs have not been routinely examined in previous studies and most are not in linkage disequilibrium with the 5-HTTLPR, thus providing independent association tests of other 5-HTT gene regions with Neuroticism-related traits (
Strug et al., 2008).